+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hydroxycarbamide"

Hydroxyurea Tablets Market - Global Forecast 2025-2030 - Product Thumbnail Image

Hydroxyurea Tablets Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 186 Pages
  • Global
From
From
Hemoglobinopathies Market - Global Forecast 2025-2032 - Product Thumbnail Image

Hemoglobinopathies Market - Global Forecast 2025-2032

  • Report
  • October 2025
  • 199 Pages
  • Global
From
Sickle Cell Treatment Market - Global Forecast to 2030 - Product Thumbnail Image

Sickle Cell Treatment Market - Global Forecast to 2030

  • Report
  • August 2025
  • 185 Pages
  • Global
From
From
Anemia Drugs Market Report 2025 - Product Thumbnail Image

Anemia Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Anemia and Other Blood Disorder Drugs Market Report 2025 - Product Thumbnail Image

Anemia and Other Blood Disorder Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Thalassemia Drugs Market Report 2025 - Product Thumbnail Image

Thalassemia Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Primary Myelofibrosis Global Market Report 2025 - Product Thumbnail Image

Primary Myelofibrosis Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
Essential Thrombocythemia (ET) Market Report 2025 - Product Thumbnail Image

Essential Thrombocythemia (ET) Market Report 2025

  • Report
  • May 2025
  • 175 Pages
  • Global
From
Hemoglobinopathies Treatment Market Report 2025 - Product Thumbnail Image

Hemoglobinopathies Treatment Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report 2025 - Product Thumbnail Image

Sickle Cell Disease Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Myelofibrosis (MF) Global Market Report 2025 - Product Thumbnail Image

Myelofibrosis (MF) Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Polycythemia Vera Drugs - Global Strategic Business Report - Product Thumbnail Image

Polycythemia Vera Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 272 Pages
  • Global
From
Sickle-Cell Anemia Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Sickle-Cell Anemia Therapeutics - Global Strategic Business Report

  • Report
  • November 2025
  • 181 Pages
  • Global
From
Sickle Cell Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Sickle Cell Disease Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 182 Pages
  • Global
From
From
Myelofibrosis - Pipeline Insight, 2025 - Product Thumbnail Image

Myelofibrosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Chronic Myelomonocytic Leukemia - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Myelomonocytic Leukemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

Hydroxycarbamide is a drug used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by inhibiting the growth of cancer cells. It is also used to treat polycythemia vera, a rare blood disorder. Hydroxycarbamide is usually taken orally in tablet form, and is usually taken once or twice a day. It is also available in an injectable form. Common side effects of hydroxycarbamide include nausea, vomiting, diarrhea, and hair loss. Hydroxycarbamide is a relatively new drug, and is still in the process of being approved by regulatory bodies in different countries. It is currently approved in the United States, Canada, and the European Union. It is also approved in some other countries, such as Australia, New Zealand, and South Africa. Hydroxycarbamide is marketed by several pharmaceutical companies, including Novartis, Bristol-Myers Squibb, and Pfizer. Other companies that market hydroxycarbamide include Cipla, Teva Pharmaceuticals, and Mylan. Show Less Read more